References

[1] Baker M. Fragment-based lead discovery grows up. Nat Rev Drug Discov. 2012;12:5.10.1038/nrd3926Suche in Google Scholar

[2] Hubbard RE, Murray JB. 20 - Experiences in fragment-based lead discovery. Fragm Based Drug Des Tools Pract Approaches Examples. 2011;493:509–31.10.1016/B978-0-12-381274-2.00020-0Suche in Google Scholar

[3] Hajduk PJ, Greer J. A decade of fragment-based drug design: strategic advances and lessons learned. Nat Rev Drug Discov. 2007;6:211–9.10.1038/nrd2220Suche in Google Scholar PubMed

[4] Hann MM, Leach AR, Harper G. Molecular complexity and its impact on the probability of finding leads for drug discovery. J Chem Inf Comput Sci. 2001;41:856–64.10.1021/ci000403iSuche in Google Scholar PubMed

[5] Fink T, Bruggesser H, Reymond JL. Virtual exploration of the small-molecule chemical universe below 160 daltons. Angew Chemie Int Ed. 2005;44:1504–8.10.1002/anie.200462457Suche in Google Scholar

[6] Congreve M, Carr R, Murray C, Jhoti H. A “Rule of Three” for fragment-based lead discovery? Drug Discov Today. 2003;8:876–7.10.1016/S1359-6446(03)02831-9Suche in Google Scholar

[7] Maly DJ, Choong IC, Ellman JA. Combinatorial target-guided ligand assembly: identification of potent subtype-selective c-Src inhibitors. Proc Natl Acad Sci USA. 2000;97:2419–24.10.1073/pnas.97.6.2419Suche in Google Scholar PubMed PubMed Central

[8] Whittaker M, Law RJ, Ichihara O, Hesterkamp T, Hallett D. Fragments: past, present and future. Drug Discov Today. 2010;7:e163–71.10.1016/j.ddtec.2010.11.007Suche in Google Scholar PubMed

[9] Bienstock RJ Overview: fragment-based drug design. ACS Symposium Series. American Chemical Society: Washington, DC, 2011.10.1021/bk-2011-1076.ch001Suche in Google Scholar

[10] Lamoree B, Hubbard RE. Current perspectives in fragment-based lead discovery (FBLD). Essays Biochem. 2017;61:453–64.10.1042/EBC20170028Suche in Google Scholar PubMed PubMed Central

[11] Alex A, Flocco M. Fragment-based drug discovery: what has it achieved so far? Curr Top Med Chem. 2007;7:1544–67.10.2174/156802607782341082Suche in Google Scholar PubMed

[12] Shuker SB, Hajduk PJ, Meadows RP, Fesik SW. Discovering high-affinity ligands for proteins: SAR by NMR. Science. 1996;274:1531–4.10.1126/science.274.5292.1531Suche in Google Scholar PubMed

[13] Davies TG, Tickle IJ. Fragment screening using X-ray crystallography. Top Curr Chem. 2012;317:33–59.10.1007/128_2011_179Suche in Google Scholar PubMed

[14] Bauman JD, Patel D, Arnold E. Fragment screening and HIV therapeutics. Top Curr Chem. 2012;317:181–200.10.1007/128_2011_232Suche in Google Scholar PubMed PubMed Central

[15] Hennig M, Ruf A, Huber W. Combining biophysical screening and X-ray crystallography for fragment-based drug discovery. Top Curr Chem. 2012;317:115–43.10.1007/128_2011_225Suche in Google Scholar PubMed

[16] Retra K, Irth H, Van Muijlwijk-Koezen JE. Technologies drug discovery surface plasmon resonance biosensor analysis as a useful tool in FBDD. Drug Discov Today. 2010;7:e181–7.10.1016/j.ddtec.2010.11.012Suche in Google Scholar

[17] Freire E. Technologies Drug Discovery Isothermal titration calorimetry: controlling binding forces in lead optimization. Drug Discov Today. 2004;1:295–9.10.1016/j.ddtec.2004.11.016Suche in Google Scholar PubMed

[18] Hofstadler SA, Sannes-Lowery KA. Applications of ESI-MS in drug discovery: interrogation of noncovalent complexes. Nat Rev Drug Discov. 2006;5:585–95.10.1038/nrd2083Suche in Google Scholar PubMed

[19] Gozalbes R, Carbajo RJ, Pineda-Lucena A. Contributions of computational chemistry and biophysical techniques to fragment-based drug discovery. Curr Med Chem. 2010;17:1769–94.10.2174/092986710791111224Suche in Google Scholar PubMed

[20] Erlanson DA, Wells JA, Braisted AC. Tethering: fragment-based drug discovery. Annu Rev Biophys Biomol Struct. 2004;33:199–223.10.1146/annurev.biophys.33.110502.140409Suche in Google Scholar PubMed

[21] Vivat Hannah V, Atmanene C, Zeyer D, Van Dorsselaer A, Sanglier-Cianférani S. Native MS: an ’ESI‚ way to support structure- and fragment-based drug discovery. Future Med Chem. 2010;2:35–50.10.4155/fmc.09.141Suche in Google Scholar PubMed

[22] Concepcion J, Witte K, Wartchow C, Choo S, Yao D, Persson H, et al. Label-free detection of biomolecular interactions using biolayer interferometry for kinetic characterization. Comb Chem High Throughput Screen. 2009;12:791–800.10.2174/138620709789104915Suche in Google Scholar PubMed

[23] Pröll F, Fechner P, Proll G. Direct optical detection in fragment-based screening. Anal Bioanal Chem. 2009;393:1557–62.10.1007/s00216-008-2477-ySuche in Google Scholar PubMed

[24] Najjar A, Platzer C, Luft A, Aßmann CA, Elghazawy NH, Erdmann F, et al. Computer-aided design, synthesis and biological characterization of novel inhibitors for PKMYT1. Eur J Med Chem. 2019;161:479–92.10.1016/j.ejmech.2018.10.050Suche in Google Scholar PubMed

[25] Schultes S, De Graaf C, Haaksma EE, De Esch IJ, Leurs R, Krämer O. Ligand efficiency as a guide in fragment hit selection and optimization. Drug Discov Today. 2010;7:157–62.10.1016/j.ddtec.2010.11.003Suche in Google Scholar

[26] Bembenek SD, Tounge BA, Reynolds CH. Ligand efficiency and fragment-based drug discovery. Drug Discov Today. 2009;14:278–83.10.1016/j.drudis.2008.11.007Suche in Google Scholar PubMed

[27] Hopkins AL, Groom CR, Alex A. Ligand efficiency: a useful metric for lead selection. Drug Discov Today. 2004;9:430–1.10.1016/S1359-6446(04)03069-7Suche in Google Scholar PubMed

[28] Crowther GJ, Rowley J, Nguyen B, Pouwer R, Pham NB, Andrews KT, et al. Fragment-based screening of a natural product library against 62 potential malaria drug targets employing native mass spectrometry. ACS Infect Dis. 2018;4:431–44.10.1021/acsinfecdis.7b00197Suche in Google Scholar PubMed PubMed Central

[29] Shultz MD. Setting expectations in molecular optimizations: strengths and limitations of commonly used composite parameters. Bioorg Med Chem Lett. 2013;23:5980–91.10.1016/j.bmcl.2013.08.029Suche in Google Scholar PubMed

[30] Leeson PD, Springthorpe B. The influence of drug-like concepts on decision-making in medicinal chemistry. Nat Rev Drug Discov. 2007;6:881–90.10.1038/nrd2445Suche in Google Scholar PubMed

[31] Orita M, Ohno K, Niimi T. Two ‘Golden Ratio’ indices in fragment-based drug discovery. Drug Discov Today. 2009;14:321–8.10.1016/j.drudis.2008.10.006Suche in Google Scholar PubMed

[32] Card GL, Blasdel L, England BP, Zhang C, Suzuki Y, Gillette S, et al. A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design. Nat Biotechnol. 2005;23:201–7.10.1038/nbt1059Suche in Google Scholar PubMed

[33] Early TR, Carr MG, O’Reilly M, Navarro EF, Maman S, Boulstridge JA, et al. Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity. J Med Chem. 2008;52:379–88.10.1021/jm800984vSuche in Google Scholar PubMed

[34] Bian Y, Xie X-Q. Computational fragment-based drug design: current trends, strategies, and applications. Aaps J. 2018;20:59.10.1208/s12248-018-0216-7Suche in Google Scholar PubMed PubMed Central

[35] Hajduk PJ, Sheppard G, Nettesheim DG, Olejniczak ET, Shuker SB, Meadows RP, et al. Discovery of potent nonpeptide inhibitors of stromelysin using SAR by NMR. J Am Chem Soc. 1997;119:5818–27.10.1021/ja9702778Suche in Google Scholar

[36] Hudson SA, Surade S, Coyne AG, McLean KJ, Leys D, Munro AW, et al. Overcoming the limitations of fragment merging: rescuing a strained merged fragment series targeting Mycobacterium tuberculosis CYP121. ChemMedChem. 2013;8:1451–6.10.1002/cmdc.201300219Suche in Google Scholar PubMed PubMed Central

[37] Najjar A, Ntie-Kang F, Sippl W. Application of computer modeling to drug discovery: case study of prk1 kinase inhibitors as potential drugs in prostate cancer treatment. In Unique Aspects of Anti-Cancer Drug Devevelopment (Jolanta Natalia Latosińska, Magdalena Latosińska). InTechOpen, 2017:18–49.10.5772/intechopen.68910Suche in Google Scholar

[38] Ertl P, Schuffenhauer A. Cheminformatics analysis of natural products: lessons from nature inspiring the design of new drugs. In: Petersen F, et al., editor. Natural compounds as drugs. Basel: Birkhäuser Basel, 2008:217–35.10.1007/978-3-7643-8595-8_4Suche in Google Scholar PubMed

[39] Harris MJ, Thompson JR, Evans JR, Whitt JA, Akee RK, Ewing TL, et al. NCI Program for natural product discovery: a publicly-accessible library of natural product fractions for high-throughput screening. ACS Chem Biol. 2018;13:2484–97.10.1021/acschembio.8b00389Suche in Google Scholar PubMed PubMed Central

[40] Newman DJ, Cragg GM. Natural products as sources of new drugs from 1981 to 2014. J Nat Prod. 2016;79:629–61.10.1021/acs.jnatprod.5b01055Suche in Google Scholar PubMed

[41] Newman DJ. From natural products to drugs. Phys Sci Rev. 2018;14:717–8.10.1515/9783110579352-006Suche in Google Scholar

[42] Lipinski CA. Rule of five in 2015 and beyond: target and ligand structural limitations, ligand chemistry structure and drug discovery project decisions. Adv Drug Deliv Rev. 2016;101:34–41.10.1016/j.addr.2016.04.029Suche in Google Scholar PubMed

[43] Laraia L, Waldmann H. Natural product inspired compound collections: evolutionary principle, chemical synthesis, phenotypic screening, and target identification. Drug Discov Today. 2017;23:75–82.10.1016/j.ddtec.2017.03.003Suche in Google Scholar PubMed

[44] Chen Y, De C, Kops B, Kirchmair J. Data resources for the computer-guided discovery of bioactive natural products. J Chem Inf Model. 2017;57:2099–111.10.1021/acs.jcim.7b00341Suche in Google Scholar PubMed

[45] Chen Y, Garcia De Lomana M, Friedrich NO, Kirchmair J. Characterization of the chemical space of known and readily obtainable natural products. J Chem Inf Model. 2018;58:1518–32.10.1021/acs.jcim.8b00302Suche in Google Scholar PubMed

[46] Olğaç A, Orhan IE, Banoglu E. The potential role of in silico approaches to identify novel bioactive molecules from natural resources. Future Med Chem. 2017;9:1663–84.10.4155/fmc-2017-0124Suche in Google Scholar PubMed

[47] Taber HW, Mueller JP, Miller PF, Arrow AS. Bacterial uptake of aminoglycoside antibiotics. Microbiol Rev. 1987;51:439–57.10.1128/mr.51.4.439-457.1987Suche in Google Scholar PubMed PubMed Central

[48] Ntie-Kang F, Nwodo JN, Ibezim A, Simoben CV, Karaman B, Ngwa VF, et al. Molecular modeling of potential anticancer agents from African medicinal plants. J Chem Inf Model. 2014;54:2433–50.10.1021/ci5003697Suche in Google Scholar PubMed

[49] Ntie-Kang F, Zofou D, Babiaka SB, Meudom R, Scharfe M, Lifongo LL, et al. AfroDb: a select highly potent and diverse natural product library from African medicinal plants. Plos One. 2013;8:e78085.10.1371/journal.pone.0078085Suche in Google Scholar PubMed PubMed Central

[50] Onguéné PA, Ntie-Kang F, Mbah JA, Lifongo LL, Ndom JC, Sippl W, et al. The potential of anti-malarial compounds derived from African medicinal plants, part III: an in silico evaluation of drug metabolism and pharmacokinetics profiling. Org Med Chem Lett. 2014;4:6.10.1186/s13588-014-0006-xSuche in Google Scholar PubMed PubMed Central

[51] Pilón-Jiménez BA, Saldívar-González FI, Díaz-Eufracio BI, Medina-Franco JL. BIOFACQUIM: a Mexican compound database of natural products. Biomolecules. 2019;9:pii: E31.10.3390/biom9010031Suche in Google Scholar PubMed PubMed Central

[52] Ntie-Kang F, Onguéné PA, Scharfe M, Owono Owono LC, Megnassan E, Mbaze LM, et al. ConMedNP: A natural product library from Central African medicinal plants for drug discovery. RSC Adv. 2014;4:409–19.10.1039/C3RA43754JSuche in Google Scholar

[53] Kang H, Tang K, Liu Q, Sun Y, Huang Q, Zhu R, et al. HIM-herbal ingredients in-vivo metabolism database. J Cheminform. 2013;5:28.10.1186/1758-2946-5-28Suche in Google Scholar PubMed PubMed Central

[54] Ye H, Ye L, Kang H, Zhang D, Tao L, Tang K, et al. HIT: linking herbal active ingredients to targets. Nucleic Acids Res. 2011;39:1055–9.10.1093/nar/gkq1165Suche in Google Scholar PubMed PubMed Central

[55] Ntie-Kang F, Telukunta KK, Döring K, Simoben CV, Moumbock AF, Malange YI, et al. NANPDB: A resource for natural products from Northern African Sources. J Nat Prod. 2017;80:2067–76.10.1021/acs.jnatprod.7b00283Suche in Google Scholar PubMed

[56] Ming H, Tiejun C, Yanli W, Stephen BH. Web search and data mining of natural products and their bioactivities in PubChem. Sci China Chem. 2013;56:10.Suche in Google Scholar

[57] Mangal M, Sagar P, Singh H, Raghava GP, Agarwal SM. NPACT: naturally occurring plant-based anti-cancer compound-activity-target database. Nucleic Acids Res. 2013;41:D1124–910.1093/nar/gks1047Suche in Google Scholar PubMed PubMed Central

[58] Zeng X, Zhang P, He W, Qin C, Chen S, Tao L, et al. NPASS: natural product activity and species source database for natural product research, discovery and tool development. Nucleic Acids Res. 2018;46:D1217–22.10.1093/nar/gkx1026Suche in Google Scholar PubMed PubMed Central

[59] Choi H, Cho SY, Pak HJ, Kim Y, Choi JY, Lee YJ, et al. NPCARE: database of natural products and fractional extracts for cancer regulation. J Cheminform. 2017;5:2.10.1186/s13321-016-0188-5Suche in Google Scholar PubMed PubMed Central

[60] Pilon AC, Valli M, Dametto AC, Pinto ME, Freire RT, Castro-Gamboa I, et al. NuBBE _DB : an updated database to uncover chemical and biological information from Brazilian biodiversity. Sci Rep. 2017;7:7215.10.1038/s41598-017-07451-xSuche in Google Scholar PubMed PubMed Central

[61] Ntie-Kang F, Onguéné PA, Fotso GW, Andrae-Marobela K, Bezabih M, Ndom JC, et al. Virtualizing the p-ANAPL library: a step towards drug discovery from african medicinal plants. PLoS One. 2014;9:e90655.10.1371/journal.pone.0090655Suche in Google Scholar PubMed PubMed Central

[62] Hatherley R, Brown DK, Musyoka TM, Penkler DL, Faya N, Lobb KA, et al. SANCDB: a South African natural compound database. J Cheminform. 2015;7:1–9.10.1186/s13321-015-0080-8Suche in Google Scholar PubMed PubMed Central

[63] Klementz D, Döring K, Lucas X, Telukunta KK, Erxleben A, Deubel D, et al. StreptomeDB 2.0 - an extended resource of natural products produced by streptomycetes. Nucleic Acids Res. 2016;44:D509–14.10.1093/nar/gkv1319Suche in Google Scholar PubMed PubMed Central

[64] Xue R, Fang Z, Zhang M, Yi Z, Wen C, Shi T. TCMID: traditional Chinese medicine integrative database for herb molecular mechanism analysis. Nucleic Acids Res. 2013;41:1089–95.10.1093/nar/gks1100Suche in Google Scholar PubMed PubMed Central

[65] Chen CY. TCM database@Taiwan: the world’s largest traditional Chinese medicine database for drug screening in silico. PLoS One. 2011;6:e15939.10.1371/journal.pone.0015939Suche in Google Scholar PubMed PubMed Central

[66] Lin Y-C, Wang -C-C, Chen I-S, Jheng J-L, Li J-H, Tung C-W. TIPdb: A database of anticancer, antiplatelet, and antituberculosis phytochemicals from indigenous plants in Taiwan. Sci World J. 2013;2013:736386.10.1155/2013/736386Suche in Google Scholar PubMed PubMed Central

[67] Gu J, Gui Y, Chen L, Yuan G, Lu HZ, Xu X. Use of natural products as chemical library for drug discovery and network pharmacology. PLoS One. 2013;8:e62839.10.1371/journal.pone.0062839Suche in Google Scholar PubMed PubMed Central

[68] Li B, Ma C, Zhao X, Hu Z, Du T, Xu X, et al. YaTCM: yet another traditional chinese medicine database for drug discovery. Comput Struct Biotechnol J. 2018;16:600–10.10.1016/j.csbj.2018.11.002Suche in Google Scholar PubMed PubMed Central

[69] Koch MA, Schuffenhauer A, Scheck M, Wetzel S, Casaulta M, Odermatt A, et al. Charting biologically relevant chemical space: A structural classification of natural products (SCONP). Proc Natl Acad Sci USA. 2005;102:17272–7.10.1073/pnas.0503647102Suche in Google Scholar PubMed PubMed Central

[70] Prescher H, Koch G, Schuhmann T, Ertl P, Bussenault A, Glick M, et al. Construction of a 3D-shaped, natural product like fragment library by fragmentation and diversification of natural products. Bioorganic Med Chem. 2017;25:921–5.10.1016/j.bmc.2016.12.005Suche in Google Scholar PubMed

[71] Schuffenhauer A, Ertl P, Roggo S, Wetzel S, Koch MA, Waldmann H. The scaffold tree - Visualization of the scaffold universe by hierarchical scaffold classification. J Chem Inf Model. 2007;47:47–58.10.1021/ci600338xSuche in Google Scholar PubMed

[72] Scott DE, Coyne AG, Hudson SA, Abell C. Fragment-based approaches in drug discovery and chemical biology. Biochemistry. 2012;51:4990–5003.10.1021/bi3005126Suche in Google Scholar PubMed

[73] Congreve M, Chessari G, Tisi D, Woodhead AJ. Recent developments in fragment-based drug discovery. J Med Chem. 2008;51:3661–80.10.1021/jm8000373Suche in Google Scholar PubMed

[74] Over B, Wetzel S, Grütter C, Nakai Y, Renner S, Rauh D, et al. Natural-product-derived fragments for fragment-based ligand discovery. Nat Chem. 2013;5:21–8.10.1038/nchem.1506Suche in Google Scholar PubMed

[75] ChEMBL Neglected Tropical Diseases. http://www.ebi.ac.uk/chemblntd. Accessed: 18 Apr 2019.Suche in Google Scholar

[76] Plouffe D, Brinker A, McNamara C, Henson K, Kato N, Kuhen K, et al. In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen. Proc Natl Acad Sci USA. 2008;105:9059–64.10.1073/pnas.0802982105Suche in Google Scholar PubMed PubMed Central

[77] Guiguemde WA, Shelat AA, Bouck D, Duffy S, Crowther GJ, Davis PH, et al. Chemical genetics of Plasmodium falciparum. Nature. 2010;465:311–5.10.1038/nature09099Suche in Google Scholar PubMed PubMed Central

[78] Gamo FJ, Sanz LM, Vidal J, De Cozar C, Alvarez E, Lavandera JL, et al. Thousands of chemical starting points for antimalarial lead identification. Nature. 2010;465:305–10.10.1038/nature09107Suche in Google Scholar PubMed

[79] Liang J, Wang M, Wang S, Li X, Meng F. Fragment-based structural optimization of a natural product itampolin A as a p38α inhibitor for lung cancer. Mar Drugs. 2019;17:53.10.3390/md17010053Suche in Google Scholar PubMed PubMed Central

[80] Bucar F, Wube A, Schmid M. Natural product isolation – how to get from biological material to pure compounds. Nat Prod Rep. 2013;30:525.10.1039/c3np20106fSuche in Google Scholar PubMed

[81] Lucas X, Gru A, Bleher S, Gu S. The purchasable chemical space: a detailed picture. J Chem Inf Model. 2015;55:915–24.10.1021/acs.jcim.5b00116Suche in Google Scholar PubMed

[82] Carreira EM. Natural products synthesis: a personal retrospective and outlook. Isr J Chem. 2018;58:114–21.10.1002/ijch.201700127Suche in Google Scholar

[83] Lear MJ, Hirai K, Ogawa K, Yamashita S, Hirama M. A convergent total synthesis of the kedarcidin chromophore: 20-years in the making. J Antibiot. (Tokyo). 2019. DOI: 10.1038/s41429-019-0175-y.Suche in Google Scholar PubMed

[84] Lewell XQ, Judd DB, Watson SP, Hann MM. RECAP: retrosynthetic combinatorial analysis procedure : a powerful new technique for identifying privileged molecular fragments with useful applications in combinatorial chemistry. J Chem Inf Comput Sci. 1998;2338:511–22.10.1002/chin.199836303Suche in Google Scholar

[85] Ertl P, Schuhmann T. A Systematic cheminformatics analysis of functional groups occurring in natural products. J Nat Prod. 2019. DOI: 10.1021/acs.jnatprod.8b01022.Suche in Google Scholar PubMed

[86] Zhu XL, Zhang R, Wu QY, Song YJ, Wang YX, Yang JF, et al. Natural product neopeltolide as a cytochrome bc 1 complex inhibitor: mechanism of action and structural modification. J Agric Food Chem. 2019;67:2774–81.10.1021/acs.jafc.8b06195Suche in Google Scholar PubMed